GenSight Biologics
Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases
Our mission is to turn scientific advances in gene therapy into novel treatments for patients with severe degenerative diseases of the eye and the central nervous system.
Our initial focus is on severe retinal diseases, with the goal of preserving or restoring vision in patients who suffer from sight-threatening ophthalmic diseases. We have been using an integrated development platform based on the combination of a gene therapy-based approach with technologies such as Mitochondrial Target Sequence (MTS) and optogenetics. We are proud of the two promising product candidates that, to date, have advanced to the stage of being tested in clinical trials. And we are investigating others.
Visit website: https://www.gensight-biologics.com/
Details last updated 04-May-2019
People at GenSight Biologics
GenSight Biologics News
Longevity.Technology looks at 12 key companies running age-related disease clinical trials in 2021
Longevity Technology - 25-Feb-2022
Approaches include senotherapeutics, stem cells and mitochondria. Eye disease is a common first target.
Read more...Gene Therapy Trial to Restore Sight in Retinitis Pigmentosa
Labiotech - 10-Jan-2018
GenSight using gene therapy and a wearable device to restore sight in patients with retinitis pig...
Read more...